Polpharma Group expanding its capacity for biologicals
Extensive biological development and production capabilities that Polpharma Group is establishing in Poland are intended not only to support its own biosimilars pipeline. The group is also creating a significant contract development and manufacturing organisation (CDMO), vice-president Hannes Teissl told Aidan Fry.
You may also be interested in...
The first of around 260 patients for a clinical trial comparing its PB006 natalizumab biosimilar candidate to Biogen’s Tysabri reference brand have been recruited by Polpharma Biologics, which has just added Karsten Roth and Alexandra Moulson to its team.
Polpharma has continued to clear the path to launching biosimilar natalizumab in Europe by prevailing in a Dutch case over a patent protecting Biogen’s Tysabri multiple sclerosis brand until 2023.
Polpharma and Sandoz have stuck a global licensing deal that gives the Novartis subsidiary rights to market the Polish firm’s biosimilar natalizumab rival to Biogen’s Tysabri.